Managing clinical grant costs

Contemporary Clinical Trials

Volumn 30, Issue 3, 2009, Pages 221-226

  Glass, Harold E ^a,b   Hollander, Karen ^c  

^a UNIVERSITY OF THE SCIENCES   (United States)

^b TTC   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Clinical grant; Clinical investigator; Clinical trial; Fair market value; Financial management

Indexed keywords

ARTICLE; CLINICAL RESEARCH; COMPENSATION; COST CONTROL; FINANCIAL MANAGEMENT; MEDICAL FEE; QUESTIONNAIRE;

BUDGETS; CLINICAL TRIALS AS TOPIC; COST CONTROL; DRUG INDUSTRY; HEALTH EXPENDITURES; HUMANS; QUESTIONNAIRES; RESEARCH PERSONNEL; RESEARCH SUPPORT AS TOPIC; UNITED STATES;

EID: 67349227399     PISSN: 15517144     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cct.2009.02.001     Document Type: Article

References (17)

1. Glass H., and Poli L. Connecting the dots. Pharm Exec (January 2007) 56-58
2. DiMasi J.A. The price of innovation: new estimates of drug development costs. J Health Econ 22 2 (2003) 151-185
3. Glass H. The importance of medical innovation in an investigator's decision to take part in clinical trials. Drug Info J 42 (2008) 537-543
4. Glass H. Higher payments to investigators don't speed study completion. Appl Clin Trials 4 11 (1995)
5. Glass H. Do clinical grant payment practices in phase 3 clinical trials influence subsequent clinical investigator prescribing behavior?. Disease Manage 7 1 (2004) 77-87
6. Corrigan M., and Glass H. Physician participation in clinical studies and subsequent prescribing of new drugs. Pharm Ther 30 1 (2005) 60-66
7. Glass H., and Dalton D. Profiles of phase IV investigators and subsequent prescribing of the study drug. J Pharm Mark Manage 17 3/4 (2006) 3-17
8. Guldal D., and Semin S. The influences of drug companies' advertising programs on physicians. Int J Health Serv 3 (2000) 585-595
9. Soumerai S.B., McLaughlin T.J., Gurwitz J.H., et al. Effect of local medical opinion leaders on quality of care for acute myocardial infarction: a randomized controlled trial. JAMA 279 (1998) 1358-1363
10. Soumerai S.B., Majumdar S.R., and Lipton H.L. Evaluating and improving physician prescribing. In: Strom B. (Ed). Pharmacoepidemiology. 3rd ed. (2000), John Wiley & Sons, Toronto, Canada 483-503
11. Greer A.L. The state of art versus the state of science: the diffusion of new medical technologies into practice. Int J Technol Assess Health Care 4 (1988) 5-26
12. Naylor C.D. Better care and better outcomes: the continuing challenge. JAMA 279 (1998) 1392-1394
13. H. Glass and J. DiFrancesco, Understanding site performance differences in multinational phase III clinical trials. Int J Pharm Med 21:(4): 279-286.
14. University of the Sciences in Philadelphia and TTC's Investigator Site Survey: http://www.ttc-llc.com/Surveys/Profiles_of_Clinical_Invs_Questionnaire.p df. July 2007.
15. University of the Sciences in Philadelphia and TTC's Investigator Site Survey Result: http://www.ttc-llc.com/Surveys/Profiles_of_Clinical_Invs_Results.pdf. July 2007.
16. Glass H., and Beaudry D. The demographic, practice, and prescribing characteristics of US clinical investigators. Drug Info J 41 (2007) 645-651
17. Glass H. Clinical grants under the microscope: what is a fair market value?. Good Clin Pract J (August 2006) 23-25